Anthony Rosenberg

Managing Director at MPM Capital L.P.

Location:
450 Kendall Street, Cambridge, Massachusetts, United States
Company:
MPM Capital L.P.
HQ Phone:
(617) 425-9200
Wrong Anthony Rosenberg?

Last Updated 11/20/2017

General Information

Education

BSc/MSc  - 

Bachelor of Science degree  - Biological Sciences , University of Leicester

Masters of Science  - Physiology , University College London

Masters of Science  - Physiology , University of London.

Affiliations

Board Member  - Radius Health Inc

Board Member  - arGEN-X N.V

Director  - IOMX

Board Member  - TRINETX INC

Global Head Business Development and Licensing  - Novartis AG

Board Member  - The BioExec Institute

Board Member  - Idenix Pharmaceuticals , Inc.

Member of the Executive Committee  - Pharma

Advisory Board Member  - Technology Vision Group LLC

BD&L At Novartis  - LinkedIn

Advisor  - Serodus ASA

Board Member  - Clinical Ink Inc

Head Partnering and Emerging Businesses, Member  - Executive Committee Novartis Pharma AG

Board Member  - Saudi Telecom Company

Board Member  - CULLINAN ONCOLOGY LLC

Member  - PEC

Web References  

iOmx Therapeutics

Tony Rosenberg
Tony Rosenberg joined MPM in 2015. Prior to joining MPM, Tony served as Global Head, M&A and Licensing (Corporate) for Novartis (NVS), based in Basel, Switzerland. In this role Tony oversaw the Novartis portfolio transformation, a comprehensive set of transactions announced in 2014 to focus Novartis on its global businesses in innovative pharmaceuticals, eye care and generics. Tony is a Board member at Clinical Ink, Radius and TriNetX and is a former board member at Idenix, all MPM portfolio companies. Tony joined Novartis predecessor company Sandoz in the U.K. in 1980, where he held diverse leadership positions across sales and marketing, business development and strategic planning. He moved to Basel in 1994, assuming roles of increasing responsibility, and in 2000 was appointed Global Head of the Transplantation and Immunology Business Unit. In 2005, Tony was appointed Global Head of Business Development and Licensing (Pharma), and managed over 30 major in-licensing transactions across therapeutic areas as well as numerous divestments. In 2010, he assumed added responsibility leading the Molecular Diagnostics Group. Tony has a Bachelor of Science degree in Biological Sciences from the University of Leicester and a Masters of Science in Physiology from the University of London.

Read More
Board of Directors | TriNetX

Tony Rosenberg
Tony Rosenberg Board Member Tony Rosenberg joined MPM in 2015. Prior to joining MPM, Tony served as Global Head, M&A and Licensing (Corporate) for Novartis (NVS), based in Basel, Switzerland. In this role Tony oversaw the Novartis portfolio transformation, a comprehensive set of transactions announced in 2014 to focus Novartis on its global businesses in innovative pharmaceuticals, eye care and generics. Tony is a Board member at Clinical Ink, Radius and TriNetX and is a former board member at Idenix, all MPM portfolio companies. Tony joined Novartis predecessor company Sandoz in the U.K. in 1980, where he held diverse leadership positions across sales and marketing, business development and strategic planning. He moved to Basel in 1994, assuming roles of increasing responsibility, and in 2000 was appointed Global Head of the Transplantation and Immunology Business Unit. In 2005, Tony was appointed Global Head of Business Development and Licensing (Pharma), and managed over 30 major in-licensing transactions across therapeutic areas as well as numerous divestments. In 2010, he assumed added responsibility leading the Molecular Diagnostics Group. Tony has a Bachelor of Science degree in Biological Sciences from the University of Leicester and a Masters of Science in Physiology from the University of London.

Read More
Cullinan Oncology Adds Industry Leaders to Board, Bringing Significant Business & Healthcare Acumen | Business Wire

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Cullinan Oncology, LLC, a company dedicated to significantly enhancing the standard of care in cancer by shepherding breakthrough science, announced today the appointment of Thomas Ebeling and Tony Rosenberg to its Board of Directors.
" We are fortunate to have both Thomas and Tony join the Cullinan board. Tony Rosenberg is a managing director at MPM Capital where he is a board member at portfolio companies Clinical Ink, iOmx Therapeutics, Radius, and TriNetX. He is also an independent board member of argenx. Prior to MPM Capital, he was Global Head, M&A and Licensing at Novartis where he oversaw the Novartis portfolio transformation, a comprehensive set of transactions, to focus the company on its global businesses in innovative pharmaceuticals, eye care, and generics. Tony joined Novartis via its predecessor company Sandoz where he held diverse leadership positions in sales and marketing, business development and strategic planning. " I'm delighted to join the board of directors of Cullinan Oncology," said Mr. Rosenberg.

Read More

Browse ZoomInfo’s Directories